Prolonged Therapy of Advanced Chronic Hepatitis C with Low-Dose Peginterferon - Wikidata - wikimedia - TriplyDB

Prolonged Therapy of Advanced Chronic Hepatitis C with Low-Dose Peginterferon

Prolonged Therapy of Advanced Chronic Hepatitis C with Low-Dose Peginterferon

http://www.wikidata.org/entity/Q27487518

about

Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C Antiviral treatment for chronic hepatitis C in patients with human immunodeficiency virus A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus Pharmacological Intervention in Hepatic Stellate Cell Activation and Hepatic Fibrosis Chronic hepatitis C virus infection: Serum biomarkers in predicting liver damage Molecular prognostic prediction in liver cirrhosis A comprehensive long-term prognosis of chronic hepatitis C patients with antiviral therapy: a meta-analysis of studies from 2008 to 2014 2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma 2014 Korean Liver Cancer Study Group-National Cancer Center Korea practice guideline for the management of hepatocellular carcinoma An IL28B genotype-based clinical prediction model for treatment of chronic hepatitis C Diagnosis, management, and treatment of hepatitis C: an update The impact of the revolution in hepatitis C treatment on hepatocellular carcinoma.Risk prediction models for hepatocellular carcinoma in different populations.Current status of novel antifibrotic therapies in patients with chronic liver disease Evolving therapies for liver fibrosis.Risk and treatment effect heterogeneity: re-analysis of individual participant data from 32 large clinical trials.Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: Analysis of data from the Hepa-C registry.Missing inaction: preventing missing outcome data in randomized clinical trials.What to do if standard therapy for hepatitis C fails.Viral hepatitis and hepatocellular carcinoma: etiology and management Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C.Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma.Linkage specific fucosylation of alpha-1-antitrypsin in liver cirrhosis and cancer patients: implications for a biomarker of hepatocellular carcinoma.Processes to manage analyses and publications in a phase III multicenter randomized clinical trial Factors that determine the development and progression of gastroesophageal varices in patients with chronic hepatitis C.HCV genome-wide genetic analyses in context of disease progression and hepatocellular carcinoma.Extended interferon-alpha therapy accelerates telomere length loss in human peripheral blood T lymphocytes.Predicting clinical outcomes using baseline and follow-up laboratory data from the hepatitis C long-term treatment against cirrhosis trial.Changes in quality of life and sexual health are associated with low-dose peginterferon therapy and disease progression in patients with chronic hepatitis C.Outcome of sustained virological responders with histologically advanced chronic hepatitis C.New antiviral therapies for chronic hepatitis C Serum vitamin D levels are not predictive of the progression of chronic liver disease in hepatitis C patients with advanced fibrosis.Rate of progression of hepatic fibrosis in patients with chronic hepatitis C: results from the HALT-C Trial Silencing of microRNA-122 enhances interferon-α signaling in the liver through regulating SOCS3 promoter methylation.A global view of hepatitis C: physician knowledge, opinions, and perceived barriers to care.Targeting the inflammation in HCV-associated hepatocellular carcinoma: a role in the prevention and treatment Long-term effects of antiviral therapy in patients with chronic hepatitis C.Sustained long-term antiviral maintenance therapy in HCV/HIV-coinfected patients (SLAM-C)S-adenosyl methionine improves early viral responses and interferon-stimulated gene induction in hepatitis C nonresponders.No increase in depression with low-dose maintenance peginterferon in prior non-responders with chronic hepatitis C.

P2860

Q24201588-AFC4C424-5D9B-42AF-B79C-893A165031F1 Q24240929-88D8AD87-FA2B-4142-9443-2EC7CF8EC2B8 Q24307721-5EAE2CB5-CD95-4D85-A030-4CA359D81809 Q26768588-489FB4EE-165B-4F38-990B-FCA913E00F3E Q26773289-77C01AA7-556B-42C2-9917-8B935EBE0FB3 Q26784251-027D51D0-4177-456A-960D-0C8545712135 Q28081137-F29E70FD-29C5-4430-AF1B-1D3A03370810 Q28392783-0FE407B4-5649-4CC2-9776-DF15A232F6AA Q28394414-5AD6B13A-5ED9-4006-812B-3CD4534330EA Q28742764-35255109-1A10-40FE-A2EA-A5239A4D6BF6 Q29619682-5AB75FBA-8529-4B23-AA25-4C02DB371AEA Q30250096-1DFDFE9E-4EAF-4C81-A511-CF5CA8BF49FD Q30383460-207D85BB-4759-4852-9E81-A4B043F3CA18 Q30473375-855E2448-7FDA-4D09-A60F-A9D172AE0626 Q30539166-79E57B12-314B-41A4-90D2-0470195AFD48 Q31112168-8A8DB8CA-E9D5-4D6C-8826-CE655CE6D714 Q31160142-74AC05CF-4877-4B2C-9F7D-D64BC387A3DF Q33534301-E941A294-2A35-4970-9684-FF7870FA9859 Q33568807-7F51DB2D-8220-402D-9B60-339F7D0F94F2 Q33593219-00F7B4AD-AD74-47A3-8FEB-694D05DE5F78 Q33618516-1DBB07CC-A25F-4F7B-9D58-4683012B39B7 Q33643368-9BE56A98-4619-4B01-9A1E-187309146D0A Q33682219-E82F0991-5EDE-4579-9D22-F82C42075858 Q33694159-6F843688-C88D-4F05-B932-53A4BDA87C9E Q33905922-0D2E6FE6-FAB4-4FA4-A2F3-89E1414B2C75 Q33982230-1E5046F8-DFE8-497A-AF26-8912ABD1D6F5 Q33988285-F9A7EB97-94D7-49A6-B36F-E451381BCCE9 Q34064042-F4A02286-5C91-403C-AF57-E0C9C61F11BF Q34072683-E0B46DE8-146C-40CF-A2AE-43EA5D787C8A Q34101701-29E6D132-C3F2-4C48-878E-6F0B19D1222C Q34130399-6DF83E36-33B8-4017-BD2D-FE8BFB1575CF Q34167963-6CF7D42E-08F4-40DD-A1CD-FF076E5DF479 Q34194979-46982FD7-CED7-4E35-8354-5C5EF36CBA51 Q34298155-DF31B10B-E4EC-4A1F-8396-36E061E0F2CB Q34322384-8D6F6A3B-8088-4BA1-A065-EFC6D07D8EF2 Q34347862-157F4AC0-A384-4919-9639-E6523F7C46EF Q34415157-AED093EB-D04C-4F2C-9CAD-9B3ADCB98042 Q34474434-B9ED7595-6018-4C21-990C-3516926760B8 Q34493348-53184BDB-8704-4FBD-9924-E9011CB1CFB2 Q34511200-13ABCAFE-3AC2-4723-87D4-3D0264948357

P2860

Prolonged Therapy of Advanced Chronic Hepatitis C with Low-Dose Peginterferon

http://www.wikidata.org/entity/Q27487518

description

2008 nî lūn-bûn

@nan

2008 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Prolonged Therapy of Advanced Chronic Hepatitis C with Low-Dose Peginterferon

@ast

Prolonged Therapy of Advanced Chronic Hepatitis C with Low-Dose Peginterferon

@en

Prolonged Therapy of Advanced Chronic Hepatitis C with Low-Dose Peginterferon

@nl

type

label

Prolonged Therapy of Advanced Chronic Hepatitis C with Low-Dose Peginterferon

@ast

Prolonged Therapy of Advanced Chronic Hepatitis C with Low-Dose Peginterferon

@en

Prolonged Therapy of Advanced Chronic Hepatitis C with Low-Dose Peginterferon

@nl

prefLabel

Prolonged Therapy of Advanced Chronic Hepatitis C with Low-Dose Peginterferon

@ast

Prolonged Therapy of Advanced Chronic Hepatitis C with Low-Dose Peginterferon

@en

Prolonged Therapy of Advanced Chronic Hepatitis C with Low-Dose Peginterferon

@nl

P1433

Q27487518-667FC41B-83BD-43D0-BB0D-3DC775C43510

P1476

Q27487518-1537956D-CFE2-46F3-96A5-EEA6BC6FC089

P2093

Q27487518-07E234D9-839A-4E38-8DFC-ECFD7910226F

Q27487518-4A31F36F-DE88-474B-84B0-AFC7A0E08502

Q27487518-4C720857-BFE0-45D4-8981-A5A30F953DCA

Q27487518-4F024525-7E64-477E-8F72-5D9CC67B4035

Q27487518-52580A30-F8C7-42FD-AE90-7EC2CB53511F

Q27487518-530939A3-EC6B-4120-BC0E-01D72109312B

Q27487518-53FD2990-E0BC-4B51-854E-9B2CCD54EC2F

Q27487518-7AB25F38-7DBA-4ED0-8E46-D28CE60E890F

Q27487518-8F663B8B-DF5D-4AE7-8010-18D1A79C2F6B

Q27487518-8F77E400-1DE5-437D-8A6B-93F165D7AA17

P2860

Q27487518-1C835F81-D898-4885-8F0D-091D99DD5FDF

Q27487518-289C6E39-4881-405A-9589-B64A65F28166

Q27487518-32454E23-ED79-4FD6-BC33-B95A3741A511

Q27487518-38A820C0-581C-4CF7-9D4A-88561AD3CB97

Q27487518-7D95F40A-D97A-463A-9DE3-CD01C3D299A0

Q27487518-7F8DBD1B-1593-4B89-8116-5E52CA6C4FF3

Q27487518-82F1150C-E60D-4E44-BF74-4C290A6BB5B9

Q27487518-A65030B9-6EC5-4AA2-9087-DE4B2FEE7CFA

Q27487518-AC842E2E-3B59-47C6-A764-A776EFD8352C

Q27487518-BC3813C3-42C4-4DE6-8221-45D736235C56

P304

Q27487518-5F8D9590-F3B9-44DE-A8AE-1A8C02477047

P31

Q27487518-D2C8B6FF-05E6-4610-9485-672363D41FF6

P3181

Q27487518-ECB2B9AF-BB37-4484-9EB9-577CA80D53CD

P356

Q27487518-E1837C49-EED9-46A0-BB03-CBF82CABD487

P407

Q27487518-584C7B4D-824A-46ED-85DC-ED6687C2A355

P433

Q27487518-7EA28F47-07C6-4D6D-A4D7-F76F9A0AB17E

P478

Q27487518-800235E6-4141-4646-B5D0-22847B53672E

P50

Q27487518-5487F929-FC78-4BE4-8E63-F619CD75D09A

Q27487518-8E18E399-570D-4373-881A-D25CD3E5AF76

P577

Q27487518-CC14D4D7-FE1E-4E81-B042-57A8D8EA5E9F

P698

Q27487518-F3812717-53E1-429B-BAE3-9EECAF51E59F

P932

Q27487518-26C854EA-DFCF-41A4-A341-FE914D869B1D

P3181

P356

P1433

The New England Journal of Medicine

P1476

Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon

@en

P2093

Anna S Lok

http://www.w3.org/2001/XMLSchema#string

Chihiro Morishima

http://www.w3.org/2001/XMLSchema#string

Elizabeth C Wright

http://www.w3.org/2001/XMLSchema#string

Gregory T Everson

http://www.w3.org/2001/XMLSchema#string

HALT-C Trial Investigators

http://www.w3.org/2001/XMLSchema#string

Herbert L Bonkovsky

http://www.w3.org/2001/XMLSchema#string

James E Everhart

http://www.w3.org/2001/XMLSchema#string

Karen L Lindsay

http://www.w3.org/2001/XMLSchema#string

Kristin K Snow

http://www.w3.org/2001/XMLSchema#string

Marc G Ghany

http://www.w3.org/2001/XMLSchema#string

P2860

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

Hepatocellular carcinoma in cirrhosis: incidence and risk factors

Histological grading and staging of chronic hepatitis

The prevalence of hepatitis C virus infection in the United States, 1999 through 2002

Transection of the oesophagus for bleeding oesophageal varices.

Global burden of disease (GBD) for hepatitis C.

Peginterferon and ribavirin for chronic hepatitis C.

Chronic hepatitis: morphology and nomenclature.

Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy.

A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia.

P304

2429-2441

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1110190

http://www.w3.org/2001/XMLSchema#string

P356

10.1056/NEJMOA0707615

http://www.w3.org/2001/XMLSchema#string

P407

P433

23

http://www.w3.org/2001/XMLSchema#string

P478

359

http://www.w3.org/2001/XMLSchema#string

P50

Adrian M. Di Bisceglie

P577

2008-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19052125

http://www.w3.org/2001/XMLSchema#string

P932

2606037

http://www.w3.org/2001/XMLSchema#string